Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROXI-PALISADE phase 3 trial of REGN7508 and REGN9933 after lower extremity revascularization in symptomatic peripheral artery disease
MOH_2026-08-20_017000Phase 3Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of REGN7508, amrecibart and rivaroxaban in arteriosclerosis obliterans (6 cohorts), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Primary endpoint not reported. Started Aug 2026; status: recruiting.
02
Drugs
REGN7508amrecibartrivaroxaban
03
Conditions
arteriosclerosis obliterans
Beyond the preview
Go deeper on MOH_2026-08-20_017000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-08-20_017000.